Method for quantitatively detecting dermatan sulfate in heparin

Abstract

The invention relates to a method quantitatively detecting dermatan sulfate in heparin, comprising the following steps according to the technical scheme: preparing detection solution of sample solution in such a way of weighting sample to be detected, dissolving the sample to be detected with ultra-pure water, adding a certain amount of sodium nitrite, adjusting the pH value of the solution to 1.0-1.5 with hydrochloric acid, stirring the solution and making the solution react for a certain time, adjusting the pH value of the solution to 6.5-7.0 with sodium hydroxide, filtering the solution with a microfiltration membrane, removing primary filtrate, and collecting subsequent filtrate; preparing detection solution of reference solution in such a way of weighting a certain amount of standarddermatan sulfate, and adding the sample solution to the standard dermatan sulfate; weighting 10 Mul of sample solution and 10 Mul of reference solution to detect the sample; and calculating the content of the dermatan sulfate with a calculating formula. The invention has the advantages that the dermatan sulfate is separated from the dermatan sulfate from the heparin with the exclusion chromatography, the undegraded dermatan sulfate is detected quantitatively and the content of the dermatan sulfate in the heparin is controlled effectively to improve the safety of the clinical use of the dermatan sulfate.

Description

1. Technical field: [0001] The invention relates to the field of biomedicine, in particular to a quantitative detection method for dermatan sulfate in heparin. 2. Background technology: [0002] Heparin and dermatan sulfate are also glycosaminoglycan drugs, both have pharmacological effects such as antithrombotic, anti-inflammatory and anti-atherosclerosis, both of which are widely found in animals, so it is easy to mix with sulfuric acid when preparing heparin dermatan, but due to the similarity in structure between the two, there is no specific quantitative detection method for the trace amount of dermatan sulfate in heparin in the current test method, so that the quality of heparin cannot be strictly and effectively controlled, making heparin in clinical use There are problems such as inaccurate measurement and repeated medication, resulting in certain medication risks. 3. Contents of the invention: [0003] The purpose of the present invention is exactly for the above...

AI Technical Summary

Problems solved by technology

[0002] Heparin and dermatan sulfate are also glycosaminoglycan drugs, both have pharmacological effects such as antithrombotic, anti-inflammatory and anti-atherosclerosis, both of which are widely found in animals, so it is easy to mix with sulfuric acid when preparing heparin dermatan, but due to the similarity in structure between the two, there is no specific quantitative detection method for the trace amount of dermatan sulfate in heparin in the current test method, so that the quality of heparin cannot be strictly and effectively controlled, making heparin in clinical use There are problems such as inaccurate measurement and repeated medication, resulting in certain medication risks

Images